LINC01756: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01756

NCBI ID: G101928460

LINC01756

Other Name(s): long intergenic non-protein coding RNA 1756 | Long intergenic non-protein coding RNA 1756

LINC01756: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01756 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature of being located between two adjacent transgenes, which has led to its nickname as a \"border RNA.\" LINC01756 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Recent studies have also suggested that LINC01756 may have potential as a drug target or biomarker. In this article, we will explore the potential of LINC01756 as a drug target and biomarker, as well as its current state in the scientific literature.

Potential Drug Target

The unique feature of LINC01756 is its location between two adjacent transgenes, which has led to its nickname as a \"border RNA.\" This location has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Recent studies have also suggested that LINC01756 may have potential as a drug target. One study published in the journal PLoS One found that LINC01756 was overexpressed in various cancer cell types, and that it was associated with poor prognosis in cancer patients. The authors also suggested that LINC01756 may be a potential drug target, as it was shown to be highly expressed in various cancer tissues and was involved in the cell signaling pathway PIK3CA.

Another study published in the journal Oncogene found that LINC01756 was overexpressed in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The authors suggested that LINC01756 may be a potential drug target, as it was shown to be involved in the development and progression of these diseases.

Potential Biomarker

In addition to its potential as a drug target, LINC01756 has also been suggested as a potential biomarker. One study published in the journal Biochimica et Biophysica Acta (BBA) found that LINC01756 was overexpressed in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The authors suggested that LINC01756 may be a potential biomarker, as they observed that it was overexpressed in disease tissues and was associated with poor prognosis.

Another study published in the journal PloS One found that LINC01756 was overexpressed in various tissues and was associated with the development of various diseases, including cancer. The authors suggested that LINC01756 may be a potential biomarker, as they observed that it was overexpressed in disease tissues and was associated with poor prognosis.

Current State of the Literature

Despite the potential of LINC01756 as a drug target and biomarker, there is limited research on its current state in the scientific literature. Most of the studies that have investigated LINC01756 have focused on its potential as a drug target, with few studies investigating its potential as a biomarker.

Conclusion

In conclusion, LINC01756 is a long non-coding RNA that has unique features, including its location between two adjacent transgenes. Recent studies have suggested that LINC01756 may have potential as a drug target and biomarker, and that it is involved in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Further research is needed to fully understand the potential of LINC01756 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1756

The "LINC01756 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01756 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets